

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

Complete if Known

09/997,490
17 Nov 2001
KINDNESS
1674

HEAT CENTER 1-800-2900

MAY 03 2002

RECEIVED

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date _____


Considered

3/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 9



Appl. No. 09/994,400

Filing Date

First Named Inventor: Kindness

Group Art Unit:

Examiner Name:

Atty. Docket No.

TECH CENTER 160012900

MAY 03 2002

RECEIVED

OTHER PRIOR ART, NON-PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

B		MASFERRER JL et al, "Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors," Cancer Research 60(5): 1306-11, March 1, 2000.	
		RUI YC, "Advances in pharmacological studies of silymarin," Mem. Inst. Oswaldo Cruz, Rio De Janeiro, Vol. 86 Suppl. II, 79-85, 1991.	
		ZI X, "A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells," Cancer Research, 58(9):1920-29 May 1, 1998.	
		HEBER, D. et al, "Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement", Am. J. Clin. Nutr. 69: 231-36 (Amer. Socy. For Clin. Nutrition) 1999.	
		HONG SH et al, "Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors," Cancer Research 59:2223-28, May 1, 1999.	
		SPARROW C. et al, "Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering," Arterioscler. Thromb. Vasc Biol. 21(1): 115-21 (Jan. 2001) (Amer. Heart Assoc. 2001).	
		WILSON, S., et al, "Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering," Arterioscler Thromb Vasc Biol. 2001;21:122-128 (January, 2001) (Amer. Heart Assoc. 2001)..	
		DEHMLOW C, et al, "Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells," Life Science 58(18): 1591-1600 (Elsevier 1996).	
h		ZHAO J et al, "Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol-13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 9



Appl. No. 09/997,440
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

MAY 03 2002

RECEIVED

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		promotion," Molecular Carcinogenesis, 26:321-333 (Wiley-Liss, Inc. 1999).	
		GRAF, B., et al., "Proinflammatory Signals Upregulate COX-2 and Increase PGE2 Production in Biphenotypic B/Macrophage Cells," Annals New York Academy of Sciences 905:294-296, April, 2000 (NY Acad. Of Sci 1999).	
		TO, K.F., CHAN, K.L., et al., "Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer," Aliment Pharmacol Ther 2001: 15:25-34, September, 2000 (Blackwell Science Ltd. 2001).	
		CHONG, R. Y., et al., "Efficacy of parenteral methotrexate in refractory Crohn's disease," Aliment Pharmacol Ther 2001: 15:35-44, September 11, 2000 (Blackwell Science Ltd. 2001).	
		BUTTAR, et al., "The "Aspirin" of the New Millennium: Cyclooxygenase-2 Inhibitors," Mayo Clinic Proceedings, 75(10): 1027-1038, October 2000, (Mayo Foundation for Medical Education and Research 2000).	
		NIE, D., "Eicosanoid Regulation of Angiogenesis in Human Prostate Carcinoma and Its Therapeutic Implications," Annals New York Academy of Sciences, 95: 165-176, April, 2000 (NY Acad. Of Sci. 2000).	
		JAULIN, N., "Reduction of the Uptake by a Macrophagic Cell Line of Nanoparticles Bearing Heparin or Dextran Covalently Bound to Poly (methyl methacrylate)," Journal of Drug Targeting, 2000, 8(3): 165-172 (Overseas Publishers Association N.V.2000) (Abstract).	
		GUPTA, R.A., et al., "Translational Studies on Cox-2 Inhibitors in the Prevention and Treatment of Colon Cancer," Annals New York Academy of Sciences, 910:196-206 (NYU Acad. Of Sci. 2000).	
		SALVEMINI, D., et al., "A Nonpeptidyl Mimic of Superoxide Dismutase with Therapeutic Activity in Rats," 286: 304-306, 8 October 1999, 306 (Amer. Assoc. for Adv. Sci. 1999).	
		HOLMER, A.F., "Researchers Are Testing 402 New Medicines for Cancer," 2001 Survey, New Medicines in Development for Cancer, p. 1-56, (Pharmaceutical Research Manufacturers America 2001).	
		VOZIYAN, PAUL A., et al., "Mechanism of Farnesol Cytotoxicity: Further Evidence for the Role of PKC-Dependent Signal	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 9



Appl. No. 09/997,990
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART AND PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

B		Transduction in Farnesol-Induced Apoptotic Cell Death," Biochemical and Biophysical Research Communication, 212(2): 479-486, July 17, 1995 (Academic Press 1995).	
		BOUNOUS, GUSTAVO, "Whey Protein Concentrate (WPC) and Glutathione Modulation in Cancer Treatment," Anticancer Research 20: 4785-4792 (2000).	
		McINTOSH, GRAEME H., et al., "Dairy Proteins Protect against Dimethylhydrazine-Induced Intestinal Cancers in Rats," [Biochemical and Molecular Roles of Nutrients] J. Nutrition 125(4):809-816 (Amer. Inst. Of Nutrition 1995).	
		HAKKAK, REZA, et al., "Diets Containing Whey Proteins or Soy Protein Isolate Protect against 7,12-Dimethylbenz(a)anthracene- induced Mammary Tumors in Female Rats," Cancer Epidemiology, Biomarkers & Prevention 9: 113-117, January 2000.	
		BOUNOUS, GUSTAVO, "Dietary Whey Protein Inhibits the Development of Dimethyl-Hydrazine Induced Malignancy," Clinical and Investigative Medicine, 11(3): 213-217 (Univ. of Toronto Press 1988).	
		McADAM, B. F., et al., "Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2," Proc. Natl. Acad. Sci. USA, 96: 272-277, January 1999 (Nat'l. Acad. Of Sci. 1999).	
		BECKMANN-KNOPP, SVANE, et al., "Inhibitory Effects of Silibinin on Cytochrome P-450 Enzymes in Human Liver Microsomes," Pharmacology & Toxicology, 2000, 86: 250-256 (Pharmacology & Toxicology 2000).	
		ZI, XIAOLIN, et al., "Modulation of Mitogen-Activated Protein Kinase Activation and Cell Cycle Regulators by the Potent Skin Cancer Preventive Agent Silymarin," Biochemical and Biophysical Research Communications 263: 528-536 (Academic Press 1999).	
		ZHAO, JIFU, et al., "Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin," Carcinogenesis, 21(4): 811-816 (Oxford University Press 2000).	
		JIANG, CHENG, et al., "Anti-Angiogenic Potential of a Cancer	

Examiner signature		31/18/03
-----------------------	--	----------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 4 of 9



Appl. No. 09/997,488
Filing Date _____
First Named Inventor: Kindness
Group Art Unit:
Examiner Name:
Atty. Docket No.

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART AND PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

g		Chemopreventive Flavonoid Antioxidant, Silymarin: Inhibition of Key Attributes of Vascular Endothelial Cells and Angiogenic Cytokine Secretion by Cancer Epithelial Cells," Biochemical and Biophysical Research Communications 276: 371-378 (Academic Press 2000).	
		SCHRIEWER H., "The effect of silybin dihemisuccinate on cholesterol biosynthesis in rat liver homogenates," Arzneimittelforschung/Drug Research 1977;27(9):1691-4, Abstract, PMID: 579140.	
		SCHRIEWER, VON H., et al., "Die Wirkung von Silybin-dihemisuccinat auf die Cholesterinbiosynthese in Rattenleberhomogenaten," Arzneim.-Forsch. Drug Res. 27 (II), Nr. 9 (1977) (Full article, German and English (no translation).	
		WAGNER et al, Zur Chemie und Analytik von Silymarin aus Silybum marianum Gaertn., Arzneim.-Forsch./Drug Res. 24 (4), (1974) 466-471. (Full article, German and English (no translation).	
		BOKEMEYER, C., et al., "Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumor activity," British Journal of Cancer (1996) 74, 2036-2041 (Stockton Press 1996).	
		SCHULTZ, H. U., et al., "Untersuchungen zum Freisetungsverhalten und zur Bioäquivalenz von Silymarin-Präparaten," Arzneim.-Forsch./Drug Res. 45 (I), Nr. 1 (1995) 61-64.	
		SHARMA DK, et al., "Hypolipidemic, anti-inflammatory, and antineoplastic activity and cytotoxicity of flavonolignans isolated from Hydnocarpus wightiana seeds," J. Nat Prod 1991 Sept-Oct; 54(5):1298-302, Nat'l Lib. Of Medicine, PMID: 1800632 (Abstract).	
		HAKOVA, H., et al., "The effect of silymarin and gamma radiation on nucleic acids in rat organs," J. Pharm. Pharmacol. (1993) 45: 910-912.	
g		BARTHOLOMAEUS, A.R., et al., "Inhibition of rat liver cytosolic glutathione S-transferase by silybin," Xenobiotica, 1994, Vol. 24,	

Examiner signature		3/18/03
-----------------------	--	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 5 of 9



Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

09/997,490

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and/or country where published	T
----------------------	-------------	--	---

<i>B</i>		No. 1, 17-24 (Taylor & Francis Ltd. 1994).	
<i>1</i>		FIEBRICH F., et al., "Silymarin, an inhibitor of prostaglandin synthetase," <i>Experientia</i> 1979 35(2) p. 1550-1552.	
<i>1</i>		RYU, HEE-SUG, et al., "High Cyclooxygenase-2 Expression in Stage 1B Cervical Cancer with Lymph Node Metastasis or Parametrial Invasion," <i>Gynecologic Oncology</i> 76, 320-325 (Academic Press 2000).	
<i>1</i>		HUTCHINS, ANDREA M., et al., "Acetyl-CoA Synthetases I and II from <i>Pyrococcus furiosus</i> ." <i>Methods in Enzymology</i> , Vol. 331, (2001) pp. 158 - 167 (Academic Press 2001).	
<i>1</i>		SHARMA, D.K., et al., "Hypolipidemic, Anti-Inflammatory, and Antineoplastic Activity and Cytotoxicity of Flavonolignans Isolated from <i>Hydnocarpus Weightiana</i> Seeds," <i>Journal of Natural Products</i> , Vol. 54, No. 5, pp. 1298-1302, Sept.-Oct. 1991.	
<i>1</i>		MANNA, SUNIL K., et al., "Silymarin Suppresses TNF-Induced Activation of NF-kB, c-Jun N-Terminal Kinase, and Apoptosis," <i>J. of Immunology</i> 163: pp. 6800-6809 (The American Association of Immunologists 1999).	
<i>1</i>		KIM, HYUN JU, et al., "Protection of Rat Liver Microsomes against Carbon Tetrachloride-Induced Lipid Peroxidation by Red Ginseng Saponin through Cytochrome P450 Inhibition," <i>Planta Medica</i> 63 (1997) 415-418 (Georg Thieme Verlag Stuttgart/New York 1997).	
<i>1</i>		GAFFNEY, DAVID K., et al., "Elevated Cyclooxygenase-2 Expression Correlates with Diminished Survival in Carcinoma of the Cervix treated with Radiotherapy," <i>Int. J. Radiation Oncology Biol. Phys.</i> , Vol. 49, No. 5, pp. 1213-1217, (Elsevier 2001).	
<i>1</i>		WONG, BRADLEY K., et al., "PSA-Specific and Non-PSA Specific Conversation of a PSA-Targeted Peptide Conjugate of Doxorubicin to its Active Metabolites," <i>Drug Metabolism and Disposition</i> 29(3): 313-318 (2001) (The American Society for Pharmacology and Experimental Therapeutics 2001).	
<i>1</i>		NELSON, ANN C., et al., "Variables in Human Liver Microsome Preparation: Impact on the Kinetics of L-a-Acetylmethadol	

Examiner signature	<i>[Signature]</i>	3/18/03
-----------------------	--------------------	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 6 of 9



Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kinda
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and/or country where published	T
----------------------	-------------	--	---

		(LAAM) N-Demethylation and Dextromethorphan O-Demethylation," Drug Metabolism and Disposition, 29: 319-315 (2001), (The American Society for Pharmacology and Experimental Therapeutics 2001).	
		CRUZ, TORCUATA, et al., "Effects of Silymarin on the Acute Stage of the Trinitrobenzenesulphonic Acid Model of Rat Colitis," Planta Med 67(1) (Feb. 6, 2001) 94-96 (Georg Thieme Verlag Stuttgart/New York 2001).	
		RUDRA, PARVEEN K., et al., "Cell-Specific Enhancement of Doxorubicin Toxicity in Human Tumour Cells by Docosahexaenoic Acid," Anticancer Research 21: 29-38 (2001).	
		BRADBURY, C. MATTHEW, et al., "Increased Activator Protein 1 Activity as Well as Resistance to Heat-induced Radiosensitization, Hydrogen Peroxide, and Cisplatin Are Inhibited by Indomethacin in Oxidative Stress-resistant Cells," Cancer Research 61, 3486-3492, April 15, 2001 (Cancer Research 2001).	
		ZI, XIAOLIN, et al., "Novel Cancer Chemopreventive Effects of a Flavonoid Antioxidant Silymarin: Inhibition of mRNA Expression of an Endogenous Tumor Promoter TNF α ," Biochemical and Biophysical Research Communications 239, 334-339 (Academic Press 1997).	
		XU, MEI FENG, et al., "Effects by doxorubicin on the myocardium are mediated by oxygen free radicals," Life Sciences 68(8) (Jan. 12, 2001) 889-901 (Elsevier 2001).	
		RASO, GIUSEPPINA MATTACE, et al., "Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1," Life Sciences 68(8) (Jan. 12, 2001) 921-931 (Elsevier 2001).	
		UCAR, MEMDUH, et al., "HMG-CoA Reductase Inhibitors and Myotoxicity," Review Article; Drug Safety 2000 Jun. 22(6): 441-457 (Adis International Limited 2000).	
		FARMER, JOHN A., et al., "Comparative Tolerability of the HMG-CoA Reductase Inhibitors," Review Article, Drug Safety 2000 Sept. 23(3) 197-213 (Adis International Limited 2000).	
		WHITTLE, B. J. R., "COX-1 and COX-2 products in the gut:	

Examiner signature		3/18/03
-----------------------	--	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 7 of 9



Appl. No

Filing D:

First Named Inventor: Kindness

Group Art Unit:

Examiner Name:

Atty. Docket No.

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

3		therapeutic impact of COX-2 inhibitors," GUT, An International Journal of Gastroenterology and Hepatology, Volume 47(3) 1 September 2000, pp. 320-325 (Gut 2000).	
		JACKSON, LUCINA M., et al., "COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs, Do They Really Offer Any Advantage?" Leading Article, Drug 2000 Jun, 59(6) 1207-1216 (Adis International Limited 2000).	
		ATTIGA, FADWA A., et al., "Inhibitors of Prostaglandin Synthesis Inhibit Human Prostate Tumor Cell Invasiveness and Reduce the Release of Matrix Metalloproteinases," Cancer Research 60, 4629-4637, August 15, 2000.	
		HSU, AO-LIN, et al., "The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2", The Journal of Biological Chemistry, 275(5) : 11397-11403, April 14, 2000 (Amer. Socy. For Biochemistry and Molecular Biology, Inc. 2000).	
		TALLY, JOHN J., et al., "4-[5-Methyl-3-phenylisoxazol-4-yl]-benzene-sulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2," J. Med. Chem, 2000, 43: 775-777 (Amer. Chem. Socy. 2000)	
		TALLY, JOHN J., et al., "N-[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration," J. Med. Chem. 2000, 43: 1661-1663 (Amer. Chem. Socy. 2000).	
		DEQUEKER, J., et al., "Improvement in Gastrointestinal Tolerability of the Selective Cyclooxygenase (COX)-2 Inhibitor, Meloxicam, Compared with Piroxicam: Results of the Safety and Efficacy Large-Scale Evaluation of COX-Inhibiting Therapies (Select) Trial in Osteoarthritis," British Journal of Rheumatology 1998; 37:946-951 (Brit. Socy. For Rheumatology 1998).	
9		MITCHELL, JANE A., et al., "Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy," British Journal of Pharmacology (1999) 128: 1121-1132 (Stockton Press 1999).	

Examiner signature		36187/03
-----------------------	--	----------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 8 of 9



Appl. No. 09/997,440
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

MAY 03 2002

RECEIVED

TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

9		HUNT, JOHN T., et al., "Discovery of (R)-7-Cyano-2, 3, 4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity," Journal of Medicinal Chemistry, 43(20): 3587-94, October 5, 2000 (Amer. Chem. Socy. 2000).	
		ZAMZAMI, NAOUFAL, et al., "Quantitation of Mitochondrial Transmembrane Potential in Cells and in Isolated Mitochondria," (Mitochondria and Apoptosis), Methods in Enzymology 322: 208-213 (Academic Press 2000).	
		ELLERBY, LISA M., et al., "Measurement of Cellular Oxidation, Relative Oxygen Species, and Antioxidant Enzymes During Apoptosis," Methods in Enzymology 322: 413-433 (Academic Press 2000).	
		DING, XIAN-ZHONG, et al., "Blockage of Cyclooxygenase-2 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells," Anticancer Research 20: 2655-2632 (2000).	
		Inhibiting COX-2, A New Discovery to Prevent Breast Cancer, American Institute for Cancer Research, NEWSLETTER, Spring 2001, Issue 71, page 10 (Amer. Inst. For Cancer Research 2001).	
		GOLDEN, BRIAN D., et al., "Selective Cyclooxygenase-2," Osteoarthritis, 25(2) 359-378 May 1999 (Rheumatic Disease Clinics of North America 1999).	
		WILLIAMS, CHRISTOPHER, et al., "The Role of COX-2 in Intestinal Cancer," Annals New York Academy of Sciences 889: 72-83 (NY Acad of Sci. 1999).	
		MASFERRER, JAIME L., et al., "COX-2 Inhibitors - A New Class of Antiangiogenic Agents," Annals New York Academy of Sciences 889: 84-86 (NY Acad of Sci. 1999).	
a		YERGEY, JAMES A., et al., "In Vitro Metabolism of the COX-2 Inhibitor DFU, Including a Novel Glutathione Adduct Rearomatization," Drug Metabolism and Disposition 29(5): 638-644 (The American Society for Pharmacology and Experimental Therapeutics 2001).	
		EDWARDS, PETER A., et al., "Sterols and Isoprenoids: Signaling	

Examiner signature		3/18/03
-----------------------	--	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 9 of 9



Appl. No. 09/997,480

Filing Date _____

First Named Inventor: Kindness

Group Art Unit: _____

Examiner Name: _____

Atty. Docket No. _____

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

B		Molecules Derived from the Cholesterol Biosynthetic Pathway," Annu. Rev. Biochem. 1999, 68: 157-185 (Annual Reviews 1999).	
		PETERSON, JEFFREY D., et al., "Glutathione Levels in Antigen- Presenting Cells Modulate Th1 Versus Th2 Response Patterns," Proc. Natl. Acad. Sci. USA 95: 3071-3076, March 1998 (Nat'l Acad. Of Sciences 1998).	
		INOUE, IKUNO, et al., "Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect Reduction of mRNA levels of interleukin-1B, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor a (PPARa) in primary endothelial cells," Life Sciences 67 (2000) 863-875 (Elsevier 2000).	
B		WILLOUGHBY, DEREK, A., et al., "COX-1, COX-2, and COX-3 and the Future Treatment of Chronic Inflammatory Disease," The Lancet Ltd., 2000, 355(9204): 646-648, 19 February 2000 (Brity. Med. Socy. 2000).	

Examiner signature		3/18/03
-----------------------	--	---------

+

RECEIVED
MAY 03 2002

MAX 0 3 2002
CH CENTER 160012300

Complete if Known

Application Number	09/997,490
Filing Date	17 nov 2001
First Named Inventor	KINDNESS
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	

Sheet	1	of	1 (other pub
-------	---	----	--------------

Attorney Docket Number

other publ. 10 sheets

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

$$3/1.8/0.3$$

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 10



Appl. No. 09/997,490
Filing Date 27/11/2001
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		BAUER G. et al, Reactive Oxygen and Nitrogen Species: Efficient, Selective, and Interactive Signals During Intercellular Induction of Apoptosis; Abteilung Virologie, Institute for Medizinische Mikrobiologie und Hygiene, Universität Freiburg, D-79104 Freiburg, Germany; <u>Anticancer Research</u> 20: 4115-4140 (2000)	
		BOLANOS JP, Nitric Oxide, Mitochondrial Function and Excitotoxicity, Methods Findings Exp. Clin Pharmacol, 22(6): 375-77 (Prous Science 2000)	
		WINK D and MITCHELL J, in "Chemical Biology of Nitric Oxide: Insights into Regulatory, Cytotoxic, and Cytoprotective Mechanisms of Nitric Oxide," Free Radical Biol. & Med. 25(4): 434-456, (Elsevier Sept. 1998)	
		VOGT A et al, "A Non-peptide Mimetic of Ras-CAAX: Selective inhibition of Farnesyl Transferase and Ras Processing," 270(2) J. Biological Chemistry 660-664 (Amer. Society For Biochemistry and Molecular Biology, Inc. Jan. 13, 1995)	
		GUNAWARDENA K et al, "Vitamin E and Other Antioxidants Inhibit Human Prostate Cancer Cells Through Apoptosis," The Prostate 44:287-295 (Wiley-Liss, Inc. 2000)	
		LIU XH et al, "Inhibition of Cyclooxygenase-2 suppresses Angiogenesis and the Growth of Prostate Cancer In Vivo," J. of Urology, 164:820-825 (Amer. Urological Ass'n Sept. 2000)	
		Abstract, MOHAMMED SI et al, "Expression of Cyclooxygenase-2 (COX-2) in Human Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder," J. Urology 164:1844-45(Amer. Urological Ass'n Nov. 2000)	
		HADDAD J et al, "Thiol Regulation of Pro-Inflammatory Cytokines Reveals a Novel Immunopharmacological Potential of Glutathione in the Alveolar Epithelium" The Journal of Pharmacology and Experimental Therapeutics, Vol. 296, No. 3, pg. 996-1005 (Amer. Socy. For Pharm. And Experimental Therapeutics 2001)	

Examiner signature		3/14/03
-----------------------	--	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 2 of 10



Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

RECEIVED
MAY 03 2002
TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

B		FOLKERS, K et al, "Survival of Cancer Patients on Therapy with Coenzyme Q ₁₀ ," Biochemical and Biophysical Research Communications; Vol. 192, No. 1, 1993, April 15, 1993, p. 241-245 (Academic Press 1993).	
		CHENG D et al, "Activation of Acyl-Coenzyme A: Cholesterol Acyltransferase by Cholesterol or by Oxysterol in a Cell-free System," <u>The Journal of Biological Chemistry</u> ; Vol. 270, No. 2, Issue of January 13, pp. 685-695, (Am. Soc'y. for Biochem. And Molecular Biol. 1995).	
		LY D et al, "Mitotic Misregulation and Human Aging," <u>Science</u> ; 31 March 2000; Vol. 287, pg. 2486-2492 (Amer. Assoc for the Adv. Of Sci.)	
		AGARWAL B et al, "Lovastatin Augments Sulindac-Induced Apoptosis in Colon Cancer Cells and Potentiates Chemopreventive Effects of Sulindac," <u>Gastroenterology</u> 1999; Vol 117:pp.838-847 (Amer. Gastroenterological Assoc.)	
		THIBAUT A et al, "Phase I Study of Lovastatin, and Inhibitor of the Mevalonate Pathway, In Patients with Cancer," <u>Clinical Cancer Research</u> ; Vol. 2, 483-491, March 1996.	
		JI Yan-Shan, XU Quing, SCHMEDTJE, J, "Hypoxia Induces High-Mobility-Group Protein I(Y) and Transcription of the Cyuclooxygenase-2 Gene in Human Vascular Endothelium," <u>Circulation Research</u> 83(3): 295-304, Aug. 10, 1998, (Amer. Heart Assoc. 1998)	
		NELSON D and COX M, Lehninger Principles of Biochemistry, (Worth Publishers NY 3 rd ed. 2000) see especially pp. 528-542, 810-814, 840-843, 856-859, 1058-1063.	
		SALWAY J, Metabolism at a Glance, (Blackwell Science Oxford London 1999) pp. 12-15, 32-33, 48-51, 60-61, 68-69, 86-89.	
		MORINI M, et al, "The role of the thiol N-acetylcysteine in the prevention of tumor invasions and angiogenesis," <u>Int'l J. of Biological Markers</u> 14(4): 268-271 (Wichtig Editore 1999)	
Q		RODAN, G and MARTIN J, "Therapeutic Approaches to Bone Diseases," <u>Science</u> 289:1508-1514 (Sept. 1, 2000 Amer. Assoc for the Adv. Of Sci.)	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 10



Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		GHOSH J and MYERS C, "Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells," Proc. Nat'l Acad. Sci. USA, 95:13182-13187 (Nat'l Acad. Of Sci. Oct.1998)	
		SALVUCCI, O., CARSANA, M., BERSANI, I., TRAGNI, G. and JANICHINI, A., "Antiapoptotic Role of Endogenous Nitric Oxide in Human Melanoma Cells," Cancer Research 61, 318, 326, January 1, 2001, (Cancer Research 2001).	
		SUZUKI, Y., KONDO, Y., HIMENO, S., NEMOTO, K., AKIMOTO, M., and IMURA, N., "Role of Antioxidant Systems in Human Androgen-Independent Prostate Cancer Cells," The Prostate 43: 144-149 (2000 Wiley-Liss, Inc.)	
		MADAAN, S., ABEL, P.D., HEWITT, C.R., STOTT, M.A., STAMP, G.W.H., and LALANI, E.N., "Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment," BJU International (2000) 736-741 (2000 BJU International)	
		SILVERSTEIN, F., FAICH, G., GOLDSTEIN, J., SIMON L., PINCUS, T., WHELTON, A., MAKUCH, R., EISEN, G., AGRAWAL, N., STENSON W., BURR, A., ZHAO, W., KENT, J., LEFKOWITH, J., VERBURG, K., GEIS, G., "Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis - The Class Study: A Randomized Controlled Trial," J. Amer. Med. Assoc., September 13, 2000 - Vol. 284, No. 10, 1247 - 1255 (Amer. Med. Assoc. 2000)	
		BOIREAU, A., BUDEDAT, P., BORDIER, F., COIMBRA, M., MEUNIER, M., IMPERATO, A., MOUSSAOUI, S., "Effects of Ebselen, a Glutathione Peroxidase Mimic, in Several Models of Mitochondrial Dysfunction," Annals of NY Acad. Sci. 893: 254 - 257 (NY Acad. Of Sci. 2000)	
		YASUDA, H., "Prevention of Neurodegeneration by a Neuroprotective Radical Scavenger," Annals NY Acad Sci. 893: 430-433 (NY Acad. Of Sci. 2000)	
		COHEN, G., and KESLER, N., "Monoamine Oxidase Inhibits	

Examiner signature		3/18/03
-----------------------	--	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 4 of 10



Appl. No. 09/997,498
Filing Date _____
First Named Inventor: Kindness _____
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

RECEIVED
MAY 03 2002
TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		Mitochondrial Respiration Annals NY Acad Sci. 893: 273-278 (NY Acad. Of Sci. 2000) .	
		LICHTENSTEIN, D. and WOLFE, M., "COX-2—Selective NSAIDs New and Improved?" (Editorial) J. Amer. Med. Assoc., September 13, 2000 – Vol. 284, No. 10, 1297 – 1299 (Amer. Med. Assoc. 2000)	
		KIRSCHENBAUM, A., KLAUSNER, A., LEE, R., UNGER, P., YAO, S., LIU, X. and LEVINE, A., "Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in the Human Prostate," 2000, Elsevier Science, Inc., p. 671-676, (Urology 56 (4) 2000)	
		GUPTA, S., SRIVASTAVA, M., AHMAD, N., BOSTWICK, D., and MUKHTAR, H., "Over-Expression of Cyclooxygenase-2 in Human Prostrate Adenocarcinoma," The Prostate 42:73-789 (2000), (2000 Wiley-Liss, Inc.)	
		ABSTRACT– CARSON, J., KULIK, G., and WEBER, M., "Antiapoptotic Signaling in LNCaP Prostate Cancer Cells: A Survival Signaling Pathway Independent of Phosphatidylinositol 3'—Kinase and Akt/Protein Kinase B," The Prostate 42:79-80 (2000 Wiley-Liss Inc.)	
		SERHAN, C., CLISH, C., BRANNON, J., COLGAN, S., CHIANG, N., and GRONERT, K., "Novel Functional Sets of Lipid-derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing," J. Exp. Med. Volume 192, Number 8, October 16, 2000 1197-1204 (The Rockefeller University Press New York).	
		KULKARNI, S., JAIN N., and SINGH, A., "Cyclooxygenase Isoenzymes and Newer Therapeutic Potential for Selective COX-2 Inhibitors," Methods Find Exp Clin Pharmacol 2000, 22(5): 291-298 (2000 Prous Science)	
		KELLOGG, G., CROWELL J., STEELE, V., LUBET, R. BOONE, CH. MALOLE W., HAWK, E., LIEBERMAN, R., LAWRENCE, J., KOPELOVICH, L., ALI, I., VINER, J. and SIGMAN, C., "Progress in Cancer Chemoprevention", Annals of NY Acad. Sci., 889: 1-13, (NY Acad. Of Sci. 2000).	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 5 of 10



Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		EARNSHAW, W., MARTINS, L. and KAUFMANN, S., "Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis," Annual Rev. Biochem 1999 68: 383- 424 (Annual Reviews (1999))	
		EDWARDS, P. and ERICSSAON, J., "Sterols and Isoprenoids: Signaling Molecules Derived From the Cholesterol Biosynthetic Pathway," Annu. Rev. Biochem. 1999, 68: 157-185 (Annual Reviews 1999) (pp. 157-175 attached)	
		STRITTMATTER, W. and ROSES, A., "Apolipoprotein e and Alzheimer disease," Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 4725- 4727, May 1995 (Nat'l Acad. Of Sci. 1995)	
		OBERLEY, T., ZHONG, W., SZWEDA, and OBERLEY, L., "Localization of Antioxidant Enzymes and Oxidative Damage Products in Normal and Malignant Prostate Epithelium," The Prostate 44: 144-155 (2000) (2000 Wiley-Liss, Inc.)	
		DENKERT, C. KOBEL, M., BERGER, S., SIEGERT, A., LECLERE, A., TREFZER, U. and HAUPTMANN, S., "Expression of Cyclooxygenase 2 in Human Malignant Melanoma," Cancer Research 61: 303-308, January 1, 2001.	
		CHINERY, R., BEAUCHAMP, R., SHYR, Y., KIRLAND, S., COFFEY, R. and MORROW, J., "Antioxidants Reduce Cyclooxygenase-2 Expression, Prostaglandin Production, and Proliferation in Colorectal Cancer Cells," Cancer Research 58: 2323-2327, June 1, 1998.	
		RAO, G., TATE, M., MURTHY, M., HEBBEL, R., and WHITE, J., "Influence of Antioxidants on Arachidonic Acid Metabolism and Platelet Function," Biochemical Medicine and Metabolic Biology 51: 74-79 (1994) (Academic Press, Inc.)	
		SADKAMOTO, W., FUJIE, K., NISHIHARA, J., HANDA, H., UEDA, N., and YAMAMOTO, S., "Effect of vitamin E on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated rat macrophages," Biochimica et Biophysica Acta 1304 (1996) 139-144 (Elsevier Science B.V. 1996)	
		PAGLIN, S., HOLLISTER, T., DELOHERY, T., HACKETT, N., McMAHILL, M., SPHICAS, E., DOMINGO, D., and YAHALOM,	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 6 of 10

Appl. No. 09/997,490


Filing Date _____

First Named Inventor: Kindn

Group Art Unit: _____

Examiner Name: _____

Atty. Docket No. _____



RECEIVED
MAY 03 2002
TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		J., "A Novel Response of Cancer Cells to Radiation Involves Autophagy and Formation of Acidic Vesicles," Cancer Research 61, 439-444, January 15, 2001	
		JOSSE, C., LEGRAND-POELS, S., PIRET, B., SLUSE, F., and PIETTE, J., "Impairment of the Mitochondrial Electron Chain Transport Prevents NF-kB Activation by Hydrogen Peroxide," Free Radical Biology & Medicine, Vol. 25, No. 1, pp. 104-112 (Elsevier Science 1998)	
		CHEN, K., SUH, J., CARR, A., MORROW, J., ZEIND, J., and FREI, B., "Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload," Am J Physical Endocrinol Metab 279: E1406-E1412, 2000 (The American Physiological Society 2000)	
		COFFEY, R., HAWKEY, C., DAMSTRUP, L. GRAVES-DEAL, R., DANIEL, V., DEMPSEY, P., CHINERY, R. KIRKLAND S., DUBOIS, R. JETTON, T. and MORROW, J., "Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells," Proc. Natl. Acad. Sci. USA Vol. 94, pp. 657-662, January 1997 (Nat'l Acad. Of Sci.).	
		MOUTET, M., D'ALESSIO, P., MALETTE, P., DEVAUX, V. and CHAUDIERE, J., "Glutathione Peroxidase Mimics Prevent TNFa- and Neutrophil-Induced Endothelial Alterations," Free Radical Biology & Medicine Vol. 25, No. 3, pp. 270-280(Elsevier 1998)	
		LANDINO, L., CREWS, B., TIMMONS, M., MORROW, J., and MARNETT, L., "Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis," Proc. Natl. Acad. Sci. USA; Vol. 93, pp. 15069-15074, December 1996 (Nat'l Acad. Of Science)	
		Zi X and AGARWAL R, "Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha," Biochem. Biophys. Res. Commun. 239(1):334-9 Oct. 9 1997 (abstract NAT'L LIB. OF MED. PUBMED PMID 9345320)	
		VALENZUELA A and GARRIDO A, "Biochemical bases of the	

Examiner signature		3/18/03
-----------------------	--	---------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 7 of 10



Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kindness _____
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____

RECEIVED
MAY 03 2002
TECH CENTER 160012900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

		pharmacological action of the flavonoid silymarin and of its structural isomer silibinin," Biol Res. 27(2): 105-112 (1994) Abstract NAT'L LIB. OF MED. PUBMED PMID: 8640239	
		FOSSLIE E, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Labor. Sci. 37(5):431-502 (CRC Press LLC 2000) [footnotes at pp. 487-502 omitted]	
		CHUNG L W K, ISAACS W and SIMONS, J (editors), "Prostate Cancer: Biology, genetics, and the New Therapeutics," ch. 21 by Brooks J and Nelson W, "Chemoprevention of Prostate Cancer," pp. 365-375 (Humana Press Totowa NJ 2001)	
		SAMBONGI Y et al, "Mechanical Rotation of the c Subunit Oligomer in ATP Synthase (F0/F1): Direct Observation," Science 286: 1722-1724, Nov 26, 1999 (Nat'l Acad. Of Sci. 1999)	
		CHAURET et al, "In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)" Bioorg. Med. Chem. Lett. 11(8): 1059-62, Apr. 23, 2001 (Abstract NAT'L LIB. OF MED. PUBMED PMID 11327589)	
		Nat'l Cancer Institute, "Interleukin-12 in Treating Patients with Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer," Study recruiting patients from www.clinical trials.gov, NLM ID NCT00003439 Jan. 1, 2001 last update	
		Nat'l Cancer Institute, "R115777 in Treating Patients with Progressive, Metastatic Prostate Cancer that has no responded to Hormone Therapy," Study recruiting patients from www.clinical trials.gov, NLM ID NCT00005848 Aug. 1, 2000 last update	
		HONG SH et al, "Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors," Cancer Research 59(9):2223-28, May 1, 1999 Abstract NAT'L LIB. OF MED. PUBMED PMID 10233261.	
		TONG M, "Induction of NAD (+) linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells," Biochem. Biophys. Res. Commun. 276(1): 77-81 (Sep. 16	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 8 of 10

Appl. No. 09/997,498
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____



RECEIVED
MAY 09 2002
TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---


		2000) Abstract NAT'L LIB. OF MED. PUBMED PMID 11006085	
		MASFERRER JL et al, "Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors," Cancer Research 60(5): 1306-11, March 1, 2000 Abstract (NAT'L LIB. OF MED. PUBMED PMID:10728691).	
		NOHL H et al, "Antioxidant-derived prooxidant formation from ubiquinol," Free Radical Biol. & Med. 25(6): 666-675 (Elsevier Science 1998)	
		TSUCHIDA S, Critical Reviews in Biochem. And Molecular Biol. 27(4,5): 337-384 (CRC Press Inc. 1992) (attached are pages 337-38, 342-343, 355-365).	
		HEBER, D et al, "Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement, Am. J. Clin. Nutr. 69(2): 231-6 Feb. 1999. Abstract NAT'L LIB. OF MED. PUBMED PMID 9989865	
		SKOTTOVA N et al, "Silymarin as a Potential Hypocholesterolaemic Drug," Physiol. Re. 47:1-7 (1998) (Inst. Of Phys., Acad. Of Sci. Czech Republic, Prague 1997).	
		DEMHLOW C, "Scavenging of Reactive Oxygen Species and Inhibition of Arachidonic Acid Metabolism by Silibinin in Human Cells," Life Sciences 58(18): 1591-1600 (Elsevier Science Inc. 1996)pp. 1591-99 attached.	
		ZHAO J and AGARWAL R, "Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention," Carcinogenesis 20(11):2101-2108 (Oxford University Press 1999)	
		AGARWAL R et al, "Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice," Carcinogenesis 15(6):1099-1103 (Oxford University Press 1994)	
		BHATIA N et al, "Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin," Cancer Letters 147 (1999): 77-84	

Examiner signature		31/18/03
-----------------------	--	----------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 9 of 10

Appl. No. 09/997,490
Filing Date _____
First Named Inventor: Kindness
Group Art Unit: _____
Examiner Name: _____
Atty. Docket No. _____



TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and/or country where published	T
----------------------	-------------	--	---

		(Elsevier Science Ireland Ltd. 1999)	
B		SOSLOW et al, "COX-2 is expressed in human pulmonary, colonic, and mammary tumors," 89(12): 2637-2645 (Dec. 15, 2000) (American Cancer Socy. 2000)	
		MILLER T et al, "5-HETE Congeners as Modulators of cell proliferation," Bioorg Med. Chem. Lett. 10(17):1913-16 (Sep. 4, 2000) abstract NAT'L LIB. OF MED. PUBMED PMID 10987416.	
		ZHAO J et al, "Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol-13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion," Mol Carcinog. 26(4):321-333, Dec. 1999 Abstract NAT'L LIB. OF MED. PUBMED PMID 10569809	
		DEHMLOW C, et al, "Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells," Life Science 58(18): 1591-1600 (1996) Abstract NAT'L LIB. OF MED. PUBMED PMID 8649189	
		YERGEY JA et al, "In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization," Drug Metab. Dispos. 29(5): 638-44, May 2001 Abstract Nat'l Lib. Of Med. PUBMED PMID 11302928	
		ZI X, "A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells," Cancer Research, 58(9):1920-29 May 1, 1998 (Abstract Nat'l Lib. Of Med. PUBMED PMID 9581834)	
		Abstract and Paper, DHAKSHINAMOORTHY et al, "Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens," 6 th Internet World Congress for Biomedical Sciences, www.uclm.es/inabis2000/symposia/ Jan 24, 2000.	
B		MANNA SK et al, "Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis," J. Immunol 163(12):6800-09 (Dec. 15, 1999) Abstract Nat'l Lib. Of Med. PUBMED PMID 10586080	

Examiner signature		3/18/03
-----------------------	--	---------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 10 of 10



Appl. No. 09/997,494
 Filing Date _____
 First Named Inventor: Kindness
 Group Art Unit: _____
 Examiner Name: _____
 Atty. Docket No. _____

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Author in CAPITAL LETTERS, title of article, title of item, date, page, vol-issue, publisher, city and /or country where published	T
----------------------	-------------	---	---

B		RUI YC, "Advances in pharmacological studies of silymarin," Mem. Inst. Oswaldo Cruz 1991:86 Sup. 2:79-85 Abstract Nat'l Lib. Of Med. PUBMED PMID 1842018	
		SPARROW C et al, "Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering," Arterioscler. Thromb. Vac. Biol. 21(1): 115-21 (Jan. 2001) Abstract Nat'l Lib. Of Med. PUBMED PMID 11145942	
		PARMENTIER M, et al, "Regulation of lipopolysaccharide- mediated interleukin-1 beta release by N-acetylcysteine in THP-1 cells," Eur. Respir. J. 16(5): 933-39, Nov. 2000 (Abstract Nat'l Lib. Of Med. PUBMED PMID 11153595)	
		HATA S et al, "Synthesis of sterols and 5-lipoxygenase products are required for the G1-S phase transition of interleukin-2-dependent lymphocyte proliferation," Microbiol Immunol. 31(12): 1231-44 (1987) (Abstract Nat'l Lib. Of Med. PUBMED PMID 3131638)	
		INOUE I et al, "Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin 1 beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells," Life Sci. 67(8): 863-76 (Jul 14, 2000) Abstract Nat'l Lib. Of Med. PUBMED PMID 10946846.	
B		BOUNOS G, "Whey Protein Concentrate (WPC) and Glutathione Modulation in Cancer Treatment, Anticancer Research 20: 4785- 4792 (2000).	

Examiner signature		3/18/03
-----------------------	--	---------